Dovato is the first oral, two-drug, single-tablet regimen approved for patients 12 years of age and older who are living with HIV-1.
FDA Approves Expanded Indication for Dovato to Include Adolescent Patients with HIV
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours